Hypoxia inducible factor-1α correlates with VEGF-C expression and lymphangiogenesis in breast cancer

Breast Cancer Research and Treatment

Volumn 99, Issue 2, 2006, Pages 135-141

  Schoppmann, Sebastian F ^a   Fenzl, Alexandra ^a   Schindl, Monika ^a   Bachleitner Hofmann, Thomas ^a   Nagy, Katalin ^a   Gnant, Michael ^a   Horvat, Reinhard ^a   Jakesz, Raimund ^a   Birner, Peter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

HIF 1 ; Lymphangiogenesis; Lymphovascular invasion; Metastasis; Prognosis; VEGF C

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METHOTREXATE; TAMOXIFEN; VASCULOTROPIN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL; LYMPHANGIOGENESIS; LYMPHATIC SYSTEM; MAJOR CLINICAL STUDY; MASTECTOMY; MICROVASCULATURE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RANK SUM TEST; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 33747589866     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9190-3     Document Type: Article

References (38)

1. Semenza GL: HIF-1 and human disease: one highly involved factor. Genes Dev 14: 1983-1991, 2000
2. Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995
3. Jiang BH, Semenza GL, Bauer C, Marti HH: Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 271: C1172-C1180, 1996
4. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992
5. Conway EM, Collen D, Carmeliet P: Molecular mechanisms of blood vessel growth. Cardiovasc Res 49: 507-521, 2001
6. Teng X, Li D, Johns RA: Hypoxia up-regulates mouse vascular endothelial growth factor D promoter activity in rat pulmonary microvascular smooth-muscle cells. Chest 121: 82S-83S, 2002
7. Currie MJ, Hanrahan V, Gunningham SP, Morrin HR, Frampton C, Han C, Robinson BA, Fox SB: Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas. J Clin Pathol 57: 829-834, 2004
8. Katsuta M, Miyashita M, Makino H, Nomura T, Shinji S, Yamashita K, Tajiri T, Kudo M, Ishiwata T, Naito Z: Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. Exp Mol Pathol 78: 123-130, 2005
9. Nilsson I, Shibuya M, Wennstrom S: Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res 299: 476-485, 2004
10. Jakesz R, Samonigg H, Gnant M, Kubista E, Depisch D, Kolb R, Mlineritsch B, Mischinger HJ, Menzel RC, Steindorfer P, Kwasny W, Tausch C, Stierer M, Taucher S, Seifert M, Hausmaninger H: Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group. Ann Surg 237: 556-564, 2003
11. Elston EW, Ellis IO: Method for grading breast cancer. J Clin Pathol 46: 189-190, 1993
12. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999
13. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G: Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60: 4693-4696, 2000
14. Horvat R, Hovorka A, Dekan G, Poczewski H, Kerjaschki D: Endothelial cell membranes contain podocalyxin - the major sialoprotein of visceral glomerular epithelial cells. J Cell Biol 102: 484-491, 1986
15. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R: Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7: 1669-1675, 2001
16. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887, 1992
17. Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36: 169-180, 1995
18. Schoppmann SF, Schindl M, Breiteneder-Geleff S, Soleima A, Breitenecker G, Karner B, Birner P: Inflammatory stromal reaction correlates with lymphatic microvessel density in early-stage cervival cancer. Anticancer Res 21: 3419-3423, 2001
19. Jakesz R, Dittrich C, Hanusch J, Kolb R, Lenzhofer R, Moser K, Rainer H, Reiner G, Schemper M, Spona J, et al. Simultaneous and sequential determinations of steroid hormone receptors in human breast cancer. Influence of intervening therapy. Ann Surg 201: 305-310, 1985
20. Jakesz R, Hausmaninger H, Haider K, Kubista E, Samonigg H, Gnant M, Manfreda D, Tschurtschenthaler G, Kolb R, Stierer M, Fridrik M, Mlineritsch B, Steindorfer P, Mittlbock M, Steger G: Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer. J Clin Oncol 17: 1701-1709, 1999
21. Kaplan E, Meier P: Non parametric estimation from incomplete observations. J Am Statist Assoc 53: 457-481, 1985
22. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G: Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8: 1831-1837, 2002
23. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E: Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 97: 1573-1581, 2003
24. Bos R, van Diest PJ, de Jong JS, van der Groep P, van der Valk P, van der Wall E: Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer. Histopathology 46: 31-36, 2005
25. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003
26. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K: Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 61: 1786-1790, 2001
27. Pepper MS: Lymphangiogenesis and tumor metastasis: myth or reality?. Clin Cancer Res 7: 462-468, 2001
28. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK: Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296: 1883-1886, 2002
29. Vleugel MM, Bos R, van der Groep P, Greijer AE, Shvarts A, Stel HV, van der Wall E, van Diest PJ: Lack of lymphangiogenesis during breast carcinogenesis. J Clin Pathol 57: 746-751, 2004
30. Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M, Jakesz R, Horvat R: Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer. Ann Surg 240: 306-312, 2004
31. van Kempen LC, Rhee JS, Dehne K, Lee J, Edwards DR, Coussens LM: Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. Differentiation 70: 610-623, 2002
32. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D: Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 161: 947-695, 2002
33. Coussens LM, Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002
34. Schoppmann SF, Fenzl A, Unger S, Bayer G, Geleff S, Gnant M, Horvat R, Jakesz R, Birner P: VEGF-C-expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival. Surgery, 2005, in press
35. Hewitson KS, Schofield CJ: The HIF pathway as a therapeutic target. Drug Discov Today 9: 704-711, 2004
36. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM: Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277: 29936-29944, 2002
37. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P: 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3: 363-375, 2003
38. Tan C, de Noronha RG, Roecker AJ, Pyrzynska B, Khwaja F, Zhang Z, Zhang H, Teng Q, Nicholson AC, Giannakakou P, Zhou W, Olson JJ, Pereira MM, Nicolaou KC, Van Meir EG: Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 65: 605-612, 2005